Omega-3 (EPA + DHA)

Skulas-Ray AC, et al. *Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.- Circulation. 2019.

Population: Adults with elevated triglycerides (including very high TG)

Dose protocol: Pharmacologic omega-3 doses (>3 g/day EPA+DHA), with emphasis on 4 g/day products

Key findings: 4 g/day EPA+DHA lowers TG ≥30% in very high TG with LDL-C increases. EPA-only did not raise LDL-C in very high TG.

Notes: Seed draft used for initial scaffold.

LOVAZA (omega-3-acid ethyl esters) FDA labeling / DailyMed (indication; LDL-C monitoring; hepatic monitoring).

Population: Severe hypertriglyceridemia per indication (≥500 mg/dL)

Dose protocol: Prescription use (commonly 4 g/day)

Key findings: Indicated to reduce TG in severe hypertriglyceridemia. LDL-C can increase and should be monitored. Liver enzymes monitored in hepatic impairment.

Notes: Labeling is not an efficacy meta-analysis. It reflects approved indication and safety monitoring statements.

Bhatt DL, et al. *Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.- (REDUCE-IT) PubMed summary. 2019.

Population: Statin-treated high-risk adults with elevated TG (trial-defined)

Dose protocol: Icosapent ethyl 2 g BID (4 g/day)

Key findings: Serious bleeding events were numerically higher (2.7% vs 2.1%, P=0.06) in the intervention group. Overall trial supports CV risk reduction in studied population.

Notes: Full text access may be restricted. Key safety and outcome summaries are consistent with major guideline discussions.

VASCEPA (icosapent ethyl) FDA labeling (bleeding-risk warning with anticoagulants/antiplatelets).

Population: Patients using prescription EPA; includes interaction warnings

Dose protocol: Prescription use, labeling includes monitoring guidance

Key findings: Label warns to monitor for bleeding with concomitant anticoagulants/antiplatelets and documents safety/interaction considerations.

Notes: Labeling informs safety protocols. Efficacy for CV risk reduction supported by RCT evidence and subsequent FDA actions.

Nicholls SJ, et al. *Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events (STRENGTH).- JAMA. 2020.

Population: Statin-treated high-risk adults with dyslipidemia (trial-defined)

Dose protocol: Omega-3 carboxylic acids (EPA+DHA) 4 g/day vs corn oil

Key findings: No significant reduction in major adverse cardiovascular events with omega-3 CA vs placebo. Contributes to "mixed CV outcomes" narrative across formulations.

Notes: High-dose omega-3 formulation differences (EPA-only vs EPA+DHA) are central to interpreting discordant outcome trials.

Manson JE, et al. *Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer (VITAL).- NEJM. 2019.

Population: Generally healthy adults (primary prevention)

Dose protocol: Marine omega-3 supplementation (trial-defined)

Key findings: No lower incidence of major cardiovascular events vs placebo in the primary analysis.

Notes: Supports limited benefit of standard-dose omega-3 supplementation for primary prevention of major CV events.

ASCEND Study Collaborative Group. *Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus (ASCEND).- NEJM. 2018.

Population: Adults with diabetes without known CVD at baseline (trial-defined)

Dose protocol: Daily omega-3 supplementation (trial-defined)

Key findings: Did not confirm cardiovascular benefit of daily omega-3 supplementation in this setting.

Notes: Complements VITAL in showing neutral primary prevention-like outcomes in major endpoints.

Appleton KM, et al. *Omega-3 fatty acids for depression in adults.- Cochrane (2021).

Population: Adults with major depressive disorder and related depressive symptom cohorts (varied)

Dose protocol: Various omega-3 formulations and doses across RCTs

Key findings: Small-to-modest effect vs placebo, but likely not clinically meaningful. Evidence is low/very low certainty with substantial heterogeneity.

Notes: Provides conservative, quality-weighted interpretation for depression claims.

Kelaiditis CF, et al. Meta-analysis of EPA-enriched omega-3 interventions for depression (EPA ≥60%). 2023.

Population: Adults with depression (trial-defined)

Dose protocol: EPA-enriched omega-3s, dose-stratified analyses reported

Key findings: Reported reduction in depression severity with EPA-enriched formulations (≥60% EPA), with dose window effects.

Notes: Heterogeneity high. Complements Cochrane by exploring formulation-specific effects.

Gencer B, et al. *Effect of Long-Term Marine ω-3 Fatty Acids on Atrial Fibrillation.- Circulation. 2021.

Population: RCT participants in omega-3 trials (including CV outcome trials)

Dose protocol: Dose-stratified (≤1 g/day vs >1 g/day)

Key findings: Marine omega-3 supplementation associated with increased AF risk in CV-outcome RCTs. Risk appears dose-related.

Notes: Key safety signal for high-dose protocols.

Jairoun AA, et al. Fish oil supplements oxidative status and compliance with GOED oxidative quality standards. 2020.

Population: Commercial fish oil supplements (product testing)

Dose protocol: N/A

Key findings: Many (but not all) tested products complied with GOED oxidative quality standards.

Notes: Applies to consumer product selection and "oxidation/purity" risk management.

Raine A, Brodrick L. Omega-3 supplementation reduces aggressive behavior: A meta-analytic review of randomized controlled trials. Aggress Violent Behav. 2024;78:101956. doi:10.1016/j.avb.2024.101956. PMID:38911617.

Population: Children and adults across community, clinical, and criminal justice settings in 28 randomized trials.

Dose protocol: Mixed EPA and DHA supplementation protocols across 28 randomized trials.

Key findings: Meta-analysis found a small but consistent reduction in aggressive behavior, with pooled effects across reactive and proactive aggression outcomes.

Notes: Useful for modernizing secondary neurobehavioral guidance, but not central to core cardiometabolic use.

Hilton JE, et al. Quantitation of EPA and DHA in fish oil dietary supplements vs label claims. 2024.

Population: Commercial fish oil products

Dose protocol: N/A

Key findings: Multiple products deviated ±20% from label claims for EPA and/or DHA.

Notes: Operationalizes "dose by EPA+DHA mg" and supports third-party testing preference.

Kong L, Zhang Q, Wang H, Xu Y, Xu C, Chen Y, Lu J, Hu S. Exploration of the optimized portrait of omega-3 polyunsaturated fatty acids in treating depression: A meta-analysis of randomized-controlled trials. J Affect Disord. 2025;379:489-501. doi:10.1016/j.jad.2025.03.006. PMID:40049535.

Population: Adults with depressive symptoms or diagnosed depression across randomized supplementation trials.

Dose protocol: Varied omega-3 formulations, with strongest signal in EPA-enriched products.

Key findings: Updated meta-analysis supported small antidepressant effects overall, with the clearest signal in EPA-enriched formulations.

Notes: Helps modernize the depression section without changing the caution around heterogeneity.

Chen C, Li X, Yan H, Liu J, Cao Y, Zhao H, Liu S, Wang Y, Sun Y, Jia B, Yuan J. Omega-3 fatty acids and cardiovascular risk-related metabolic markers in diverse populations: a meta-analysis of randomized trials. Nutr Metab Cardiovasc Dis. 2026;36(4):104488. doi:10.1016/j.numecd.2025.104488. PMID:41494879.

Population: Diverse adult populations across 24 randomized trials assessing omega-3 effects on cardiovascular-related metabolic markers.

Dose protocol: Varied EPA and DHA formulations across 24 randomized trials.

Key findings: Recent meta-analysis reinforced triglyceride lowering and showed smaller favorable shifts in HDL and selected subgroup LDL outcomes.

Notes: Supports keeping the omega-3 cardiometabolic framing focused on triglycerides rather than overselling broad cardiovascular transformation.

Calderon Martinez E, et al. The effects of omega-3, DHA, EPA, Souvenaid in Alzheimer's disease: A systematic review and meta-analysis. Neuropsychopharmacol Rep. 2024;44(3):457-468. doi:10.1002/npr2.12455. PMID:38924283.

Population: Patients with Alzheimer's disease.

Dose protocol: Omega-3/EPA/DHA supplementation in Alzheimer's disease patients across 14 studies.

Key findings: Moderate effect on CDR-measured cognitive decline (SMD = -0.41). No significant effects on MMSE, ADAS-cog, or activities of daily living.

Notes: Adds a cognitive decline signal in AD populations. Inconsistency across scales limits confidence.